Emerging stimulation paradigms such as burst and high-frequency stimulation present promising alternatives for patients with ineffective SCS systems. In cases wherein the existing device cannot support these modalities, an IPG externalization trial may serve as a low-risk strategy to potentially rescue and optimize therapy.
Kankam et al. (Thu,) studied this question.